Targeting the LPI/GPR55 Axis in MAFLD and MASH: Novel Insights, Therapeutic Strategies and Future Directions.
| Journal | Liver international: official journal of the International Association for the Study of the Liver |
| Study Type | Clinical Study |
| Population | Human participants |
This research identifies a specific cannabinoid-related pathway (LPI/GPR55) that drives progression from fatty liver to more severe inflammatory liver disease. Understanding this mechanism could lead to targeted interventions for the millions of patients with metabolic liver disease.
This clinical study examined the L-α-lysophosphatidylinositol/GPR55 receptor axis, part of the broader endocannabinoid system, in human participants with metabolic dysfunction-associated fatty liver disease (MAFLD). The research demonstrates that this pathway promotes harmful liver changes including fat accumulation, inflammation, and scarring across multiple liver cell types. The study also identified that the enzyme MBOAT7 worsens disease progression by modifying this pathway, leading to increased liver fat storage and insulin resistance.
“While this advances our understanding of how endocannabinoid-related pathways contribute to liver disease, it doesn’t immediately change my clinical approach. The therapeutic implications remain theoretical until we have interventional data.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
What is the LPI/GPR55 axis, and how does it relate to cannabinoids?
The LPI/GPR55 axis is the L-α-lysophosphatidylinositol/GPR55 receptor axis, which the article describes as part of the broader endocannabinoid system. This research examined the axis in human participants with metabolic dysfunction-associated fatty liver disease, known as MAFLD, to understand how this cannabinoid-related pathway contributes to liver disease.
How does the LPI/GPR55 pathway affect the liver in fatty liver disease?
The article reports that this pathway promotes harmful liver changes, including fat accumulation, inflammation, and scarring, and that these effects occur across multiple types of liver cells. It describes the pathway as driving progression from fatty liver to more severe inflammatory liver disease.
What role does the enzyme MBOAT7 play in fatty liver disease?
The study identified MBOAT7 as an enzyme that worsens disease progression by modifying the LPI/GPR55 pathway. According to the article, this modification leads to increased fat storage in the liver and to insulin resistance, both of which are part of how MBOAT7 makes metabolic dysfunction-associated fatty liver disease worse.
Is there a treatment that targets this pathway for liver disease yet?
Not yet. The article says that understanding this mechanism could lead to targeted interventions for the millions of patients with metabolic liver disease, but it presents this as a future possibility. Specific drug treatments aimed at this pathway still await further research, so the findings do not yet translate into a new therapy.
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
